

Revision date: 25-Mar-2013 Version: 2.0 Page 1 of 9

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc Pfizer Ltd
Pfizer Pharmaceuticals Group Ramsgate Road
235 East 42nd Street Sandwich, Kent
New York, New York 10017 CT13 9NJ
1-212-573-2222 United Kingdom

+00 44 (0)1304 616161
Emergency telephone number: Emergency telephone number:

CHEMTREC (24 hours): 1-800-424-9300 International CHEMTREC (24 hours): +1-703-527-3887
Contact E-Mail: pfizer-MSDS@pfizer.com

Material Name: Clindamycin Phosphate Topical Solution

Trade Name: CLEOCIN T; DALACIN T

Chemical Family: Mixture

Intended Use: Pharmaceutical product used as antibiotic agent

2. HAZARDS IDENTIFICATION

Appearance: Colorless solution Signal Word: WARNING

Statement of Hazard: Flammable liquid and vapor.

Causes eye irritation.

Vapors may cause drowsiness and irritation of the eyes or respiratory tract

May cause allergic reaction.

Additional Hazard Information:

Short Term: May be harmful if swallowed. May cause skin irritation. Vapors irritating to eyes and respiratory

tract. Breathing high vapor concentrations may cause central nervous system (CNS) depression resulting in dizziness, light-headedness, headache, nausea, and loss of coordination. Continued inhalation may result in unconsciousness and death.

Known Clinical Effects: Individuals sensitive to this material or other materials in its chemical class may develop

allergic reactions. Clinical use of this drug has caused sore throat, fever, gastrointestinal disturbances, abnormal liver function tests, kidney dysfunction. Pseudomembranous colitis (manifested by watery diarrhea, urge to defecate, abdominal cramps, low-grade fever, bloody

stools, and abdominal pain) may also occur.

EU Indication of danger: Irritant

EU Hazard Symbols:

Xi

EU Risk Phrases:

Material Name: Clindamycin Phosphate Topical Solution

Revision date: 25-Mar-2013 Version: 2.0

2. HAZARDS IDENTIFICATION

R10 - Flammable.

R36 - Irritating to eyes.

R43 - May cause sensitization by skin contact. R67 - Vapors may cause drowsiness and dizziness.

Australian Hazard Classification

(NOHSC):

Hazardous Substance. Dangerous Goods.

Note: This document has been prepared in accordance with standards for workplace safety, which

require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your

Page 2 of 9

workplace.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	%
Clindamycin Phosphate	24729-96-2	246-433-0	Xi;R36-43 Xn:R22	1
			,	
Propylene glycol	57-55-6	200-338-0	Not Listed	*
Isopropyl alcohol	67-63-0	200-661-7	F;R11 R67 Xi;R36	50

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	%
Water, purified	7732-18-5	231-791-2	Not Listed	*

Additional Information: * Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace

safety.

For the full text of the R phrases mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. If irritation occurs or

persists, get medical attention.

Skin Contact: Remove contaminated clothing and wash exposed area with soap and water. Obtain medical

assistance if irritation occurs.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not

induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards

Identification and/or Section 11 - Toxicological Information.

Material Name: Clindamycin Phosphate Topical Solution

Revision date: 25-Mar-2013 Version: 2.0

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: Emits toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides, sulfur oxides and other

sulfur-containing compounds.

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-

contained breathing apparatus.

Fire / Explosion Hazards: Flammable liquid. Vapors will form flammable or explosive mixtures with air at room

temperature. Vapors are heavier than air and may travel along surfaces to remote ignition

Page 3 of 9

sources and flash back.

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see

Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Eliminate possible ignition sources (e.g., heat, sparks, flame, impact, friction, electricity).

Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill

area thoroughly.

Measures for Environmental

Protections:

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to

avoid environmental release.

Additional Consideration for Large

Spills:

Non-essential personnel should be evacuated from affected area. Report emergency

situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

General Handling: Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use

appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or

other equivalent controls.

Storage Conditions: Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

Clindamycin Phosphate

Pfizer OEL TWA-8 Hr: 100μg/m³

Propylene glycol

Australia TWA 150 ppm

474 mg/m³ 10 mg/m³

Ireland OEL - TWAs 150 ppm 470 mg/m³

470 mg/m³ 10 mg/m³

Latvia OEL - TWA 7 mg/m³ **Lithuania OEL - TWA** 7 mg/m³

OUNDAM/ON DUOCRUATE TORION COLUTION

Material Name: Clindamycin Phosphate Topical Solution

Revision date: 25-Mar-2013

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Isopropyl alcohol

ACGIH Threshold Limit Value (TWA) 200 ppm 400 ppm **ACGIH Threshold Limit Value (STEL) ACGIH - Biological Exposure Limit:** 40 mg/L 500 ppm **Australia STEL** 1230 mg/m³ Australia TWA 400 ppm 983 mg/m³ Austria OEL - MAKs 200 ppm 500 mg/m³ 200 ppm **Belgium OEL - TWA** 500 mg/m³ 980.0 mg/m³ **Bulgaria OEL - TWA** Czech Republic OEL - TWA 500 mg/m³ **Denmark OEL - TWA** 200 ppm 490 mg/m³ Estonia OEL - TWA 150 ppm 350 mg/m³ **Finland OEL - TWA** 200 ppm 500 mg/m³ Germany - TRGS 900 - TWAs 200 ppm 500 mg/m³ 200 ppm Germany (DFG) - MAK 500 mg/m³ **Germany - Biological Exposure Limit:** 50 mg/L **Greece OEL - TWA** 400 ppm 980 mg/m³ **Hungary OEL - TWA** 500 mg/m³ Ireland OEL - TWAs 200 ppm Japan - OELs - Ceilings 400 ppm 980 mg/m³ 350 mg/m³ Latvia OEL - TWA Lithuania OEL - TWA 150 ppm 350 mg/m³ **OSHA - Final PELS - TWAs:** 400 ppm 980 mg/m³ Poland OEL - TWA 900 mg/m³ Portugal OEL - TWA 200 ppm Romania OEL - TWA 81 ppm 200 mg/m³ Romania - Biological Exposure Limit: 50 mg/L Slovakia OEL - TWA 200 ppm 500 mg/m³ 200 ppm Slovenia OEL - TWA 500 mg/m³ Spain OEL - TWA 200 ppm 500 mg/m³ **Spain - Biological Exposure Limit:** 40 mg/L Sweden OEL - TWAs 150 ppm 350 mg/m³

Analytical Method: Analytical method available for clindamycin. Contact Pfizer Inc for further information.

Page 4 of 9

Version: 2.0

Material Name: Clindamycin Phosphate Topical Solution

Revision date: 25-Mar-2013 Version: 2.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Engineering Controls: Engineering controls should be used as the primary means to control exposures. General

room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne

Page 5 of 9

contamination levels below the exposure limits listed above in this section.

Environmental Exposure Controls: Refer to specific Member State legislation for requirements under Community environmental

legislation.

Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal

protective equipment (PPE).

Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk

processing operations.

Eyes: Wear safety glasses or goggles if eye contact is possible.

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and

for bulk processing operations.

Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate

respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:SolutionColor:ColorlessOdor:Characteristic alcohol odorMolecular Formula:Mixture

Molecular Weight: Mixture

Flash Point (Liquid) (°C): 24 Closed cup

Upper Explosive Limits (Liquid) (% by Vol.): 12.7 Lower Explosive Limits (Liquid) (% by Vol.): 2

10. STABILITY AND REACTIVITY

Chemical Stability: Stable under normal conditions of use.

Conditions to Avoid: Keep away from heat, spark, flames and all other sources of ignition. Fine particles (such as

dust and mists) may fuel fires/explosions.

Incompatible Materials: Oxidising agents, Acids, Bases.

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual

ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Clindamycin Phosphate

Rat Oral LD 50 1832 mg/kg

Rat Para-periosteal LD 50 321 mg/kg Rat Intraperitoneal LD 50 745 mg/kg Mouse Oral LD 50 2359 mg/kg Mouse Intravenous LD 50 820 mg/kg

Isopropyl alcohol

Rat Oral LD50 > 2000 mg/kg

Material Name: Clindamycin Phosphate Topical Solution

Revision date: 25-Mar-2013 Version: 2.0

11. TOXICOLOGICAL INFORMATION

Mouse Oral LD50 3600 mg/kg
Rat Inhalation LC50-8h 16,000 ppm
Rabbit Dermal LD50 12800 mg/kg
Rat Inhalation LC50 30 mg/L

Propylene glycol

Mouse Oral LD50 22,000 mg/kg Rat Oral LD50 20,000 mg/kg Rabbit Dermal LD50 20,800 mg/kg

Acute Toxicity Comments: A

A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable

Page 6 of 9

at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Clindamycin Phosphate

Eye Irritation Rabbit Moderate Skin Irritation Rabbit Mild

Isopropyl alcohol

Eye Irritation Rabbit Severe Skin Irritation Rabbit Mild

Propylene glycol

Skin Irritation Rabbit Mild Eye Irritation Rabbit Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Clindamycin Phosphate

6 Month(s) Rat Oral 600 mg/kg/day NOAEL No effects at maximum dose 6 Month(s) Dog Oral 600 mg/kg/day NOAEL Gastrointestinal system

Isopropyl alcohol

20 Week(s) Rat Inhalation 4000 ppm NOAEL Liver, Central nervous system 104 Week(s) Rat Inhalation 5000 ppm Kidney

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Clindamycin Phosphate

Subcutaneous 250 mg/kg Prenatal & Postnatal Development NOAEL Rat Not teratogenic Prenatal & Postnatal Development Oral 300 mg/kg/day Rat NOAEL Not Teratogenic Prenatal & Postnatal Development Mouse Oral 600 mg/kg/day NOAEL Not Teratogenic Subcutaneous 5 mg/kg/day Prenatal & Postnatal Development Rabbit NOAEL Not Teratogenic, Maternal Toxicity Reproductive & Fertility Rat Oral 300 mg/kg/day NOAEL No effects at maximum dose

Isopropyl alcohol

Prenatal & Postnatal Development Rat Inhalation 7,000 ppm LOAEL Maternal toxicity, Fetotoxicity, Embryotoxicity 2 Generation Reproductive Toxicity Rat Oral 1000 mg/kg/day LOAEL Maternal Toxicity, Fetal mortality No effects at maximum dose Prenatal & Postnatal Development Rat Oral 1200 mg/kg/day NOAEL

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Clindamycin Phosphate

Material Name: Clindamycin Phosphate Topical Solution

Revision date: 25-Mar-2013 Version: 2.0

11. TOXICOLOGICAL INFORMATION

Bacterial Mutagenicity (Ames) Salmonella Negative

In Vitro Micronucleus Rat Negative

Isopropyl alcohol

Bacterial Mutagenicity (Ames) Salmonella Negative

Mammalian Cell Mutagenicity HGPRT Chinese Hamster Ovary (CHO) cells Negative

In Vitro Sister Chromatid Exchange Negative

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

See below

Isopropyl alcohol

IARC: Group 3 (Not Classifiable)

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been thoroughly investigated. Releases to the environment

should be avoided.

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State

specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental

Page 7 of 9

releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all categories of classifications unless specified below.

This material is regulated for transportation as a hazardous material/dangerous good.

UN number: UN 1993

UN proper shipping name: Flammable liquid, n.o.s. (contains isopropanol)

Transport hazard class(es): 3
Packing group: III
Flash Point (°C): 24

Exceptions: For small quantities packed in combination packaging, exceptions may apply. Please refer to the applicable dangerous

 $goods \ regulations \ for \ additional \ information.$

Flash Point (°C): 24

15. REGULATORY INFORMATION

EU Symbol: Xi

Material Name: Clindamycin Phosphate Topical Solution

Revision date: 25-Mar-2013 Version: 2.0

15. REGULATORY INFORMATION

EU Indication of danger: Irritant

EU Risk Phrases:

R10 - Flammable. R36 - Irritating to eyes.

R43 - May cause sensitization by skin contact. R67 - Vapors may cause drowsiness and dizziness.

EU Safety Phrases:

S16 - Keep away from sources of ignition - No smoking.

S24/25 - Avoid contact with eyes and skin.

S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical

Page 8 of 9

advice.

S36/37 - Wear suitable protective clothing and gloves.

OSHA Label:

WARNING

Flammable liquid and vapor.

Causes eye irritation.

Vapors may cause drowsiness and irritation of the eyes or respiratory tract

May cause allergic reaction.

Canada - WHMIS: Classifications

WHMIS hazard class:

Class B, Division 2

Class D, Division 2, Subdivision B



Clindamycin Phosphate

EU EINECS/ELINCS List 246-433-0

Propylene glycol

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS/ELINCS List

Present
200-338-0

Water, purified

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

REACH - Annex IV - Exemptions from the

Present

Present

obligations of Register:

EU EINECS/ELINCS List 231-791-2

Isopropyl alcohol

Material Name: Clindamycin Phosphate Topical Solution Page 9 of 9
Revision date: 25-Mar-2013 Version: 2.0

15. REGULATORY INFORMATION

CERCLA/SARA 313 Emission reporting 1.0 %
Inventory - United States TSCA - Sect. 8(b) Present
Australia (AICS): Present
EU EINECS/ELINCS List 200-661-7

16. OTHER INFORMATION

Text of R phrases mentioned in Section 3

R11 - Highly flammable.

R22 - Harmful if swallowed.

R36 - Irritating to eyes.

R43 - May cause sensitization by skin contact. R67 - Vapors may cause drowsiness and dizziness.

Data Sources: Publicly available toxicity information. Pfizer proprietary drug development information. Safety

data sheets for individual ingredients.

Reasons for Revision: Updated Section 14 - Transport Information. Updated Section 10 - Stability and Reactivity.

Prepared by: Product Stewardship Hazard Communication

Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet